Biomm (BIOM3) reported this Wednesday, July 22, 2026, on the effects of the enactment of Law 15,471/2026 on its operations involving PDPs (Productive Development Partnerships). With the new legislation, the PDP program, through which the company supplies human insulin and insulin glargine to the SUS, now has the status of law which, according to the company, brings greater stability and predictability to its revenues.
Biomm stated that, in line with the new PDP legal framework, it will start publishing its contracted supply backlog, defined as the difference between the volume of products contracted by the Ministry of Health, as per signed contracts, and the volume of units already delivered.
The law also created the category of Strategic Health Company (EES), with formal qualification for sector companies that meet requirements such as having an industrial plant in Brazil, a track record in research and development, and the capacity to ensure continuity in the supply of strategic drugs. Among the benefits for companies qualified as EES are access to specific credit lines via BNDES, regulatory priority at Anvisa and priority in public funding calls.
Another highlighted point is that Law 15,471 established clearer rules for technology transfer in PDPs, requiring full access to the know-how and production technology of participating foreign laboratories, as well as transfer and unrestricted access to the Master Cell Bank for biotechnological products. Biomm stated that its current contracts already provide for full technology transfer from international partners to Brazilian public laboratories, with no need for renegotiation.
At the moment, Biomm is awaiting publication by the Ministry of Health of the operating procedures for accreditation as a Strategic Health Company and reported that it will keep the market informed about the next steps related to this process.
